Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations

Objective: The latest nonnucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV) is indicated for human immunodeficiency virus type-1 (HIV-1) patients initiating antiretroviral treatment, but the extent of genotypic RPV resistance in treatment-naive patients outside clinical trials is p...

Descripción completa

Detalles Bibliográficos
Autores principales: Theys, Kristof, Van Laethem, Kristel, Gomes, Perpetua, Baele, Guy, Pineda-Peña, Andrea-Clemencia, Vandamme, Anne-Mieke, Camacho, Ricardo J., Abecasis, Ana B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc. 2016
Materias:
Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845676/
https://www.ncbi.nlm.nih.gov/pubmed/26651266
http://dx.doi.org/10.1089/aid.2015.0095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845676/
https://www.ncbi.nlm.nih.gov/pubmed/26651266
http://dx.doi.org/10.1089/aid.2015.0095

Ejemplares similares